BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 23490445)

  • 1. Positron emission tomographic imaging of iodine 124 anti-prostate stem cell antigen-engineered antibody fragments in LAPC-9 tumor-bearing severe combined immunodeficiency mice.
    Fonge H; Leyton JV
    Mol Imaging; 2013 May; 12(3):191-202. PubMed ID: 23490445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors.
    Leyton JV; Olafsen T; Lepin EJ; Hahm S; Bauer KB; Reiter RE; Wu AM
    Clin Cancer Res; 2008 Nov; 14(22):7488-96. PubMed ID: 19010866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors.
    Lepin EJ; Leyton JV; Zhou Y; Olafsen T; Salazar FB; McCabe KE; Hahm S; Marks JD; Reiter RE; Wu AM
    Eur J Nucl Med Mol Imaging; 2010 Aug; 37(8):1529-38. PubMed ID: 20354850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applications of immunoPET: using 124I-anti-PSCA A11 minibody for imaging disease progression and response to therapy in mouse xenograft models of prostate cancer.
    Knowles SM; Tavaré R; Zettlitz KA; Rochefort MM; Salazar FB; Jiang ZK; Reiter RE; Wu AM
    Clin Cancer Res; 2014 Dec; 20(24):6367-78. PubMed ID: 25326233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibody.
    Knowles SM; Zettlitz KA; Tavaré R; Rochefort MM; Salazar FB; Stout DB; Yazaki PJ; Reiter RE; Wu AM
    J Nucl Med; 2014 Mar; 55(3):452-9. PubMed ID: 24504052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti-Prostate Stem Cell Antigen Cys-Diabody.
    Zettlitz KA; Tsai WK; Knowles SM; Kobayashi N; Donahue TR; Reiter RE; Wu AM
    J Nucl Med; 2018 Sep; 59(9):1398-1405. PubMed ID: 29602820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody.
    Olafsen T; Gu Z; Sherman MA; Leyton JV; Witkosky ME; Shively JE; Raubitschek AA; Morrison SL; Wu AM; Reiter RE
    J Immunother; 2007; 30(4):396-405. PubMed ID: 17457214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [
    Zettlitz KA; Tsai WK; Knowles SM; Salazar FB; Kobayashi N; Reiter RE; Wu AM
    Mol Imaging Biol; 2020 Apr; 22(2):367-376. PubMed ID: 31209779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors.
    Leyton JV; Olafsen T; Sherman MA; Bauer KB; Aghajanian P; Reiter RE; Wu AM
    Protein Eng Des Sel; 2009 Mar; 22(3):209-16. PubMed ID: 18957406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiolabeled anti-claudin 4 and anti-prostate stem cell antigen: initial imaging in experimental models of pancreatic cancer.
    Foss CA; Fox JJ; Feldmann G; Maitra A; Iacobuzio-Donohue C; Kern SE; Hruban R; Pomper MG
    Mol Imaging; 2007; 6(2):131-9. PubMed ID: 17445507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice.
    Sundaresan G; Yazaki PJ; Shively JE; Finn RD; Larson SM; Raubitschek AA; Williams LE; Chatziioannou AF; Gambhir SS; Wu AM
    J Nucl Med; 2003 Dec; 44(12):1962-9. PubMed ID: 14660722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Dual-Modality Linker Enables Site-Specific Conjugation of Antibody Fragments for
    Zettlitz KA; Waldmann CM; Tsai WK; Tavaré R; Collins J; Murphy JM; Wu AM
    J Nucl Med; 2019 Oct; 60(10):1467-1473. PubMed ID: 30877181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual-Modality ImmunoPET/Fluorescence Imaging of Prostate Cancer with an Anti-PSCA Cys-Minibody.
    Tsai WK; Zettlitz KA; Tavaré R; Kobayashi N; Reiter RE; Wu AM
    Theranostics; 2018; 8(21):5903-5914. PubMed ID: 30613270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts.
    Saffran DC; Raitano AB; Hubert RS; Witte ON; Reiter RE; Jakobovits A
    Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2658-63. PubMed ID: 11226295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Redirection of CD4+ and CD8+ T lymphocytes via a novel antibody-based modular targeting system triggers efficient killing of PSCA+ prostate tumor cells.
    Arndt C; Feldmann A; Töpfer K; Koristka S; Cartellieri M; Temme A; Ehninger A; Ehninger G; Bachmann M
    Prostate; 2014 Sep; 74(13):1347-58. PubMed ID: 25053504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 124I-HuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: preliminary results.
    Zou P; Povoski SP; Hall NC; Carlton MM; Hinkle GH; Xu RX; Mojzisik CM; Johnson MA; Knopp MV; Martin EW; Sun D
    World J Surg Oncol; 2010 Aug; 8():65. PubMed ID: 20691066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The therapeutic efficacy of I131-PSCA-mAb in orthotopic mouse models of prostate cancer.
    Yu S; Feng F; Wang K; Men C; Lin C; Liu Q; Yang D; Gao Z
    Eur J Med Res; 2013 Dec; 18(1):56. PubMed ID: 24330823
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.